Home / Transcripts / Alpha Cognition Inc. (ACOG) · August 13, 2026

Alpha Cognition Inc. (ACOG) Earnings Call Transcript

August 13, 2026

NASDAQ US Health Care Biotechnology earnings 41 min

Earnings Call Speaker Segments

Henry Du executive
#1

Thanks, Sachi. Hello, everybody, and we appreciate your presence on this call covering Alpha Cognition's financial results for the second quarter of 2026. Earlier today, once the market had closed, we put out a press release sharing those results. Joining me are Michael McFadden, who serves as Alpha Cognition's Chief Executive Officer, along with our Chief Operating Officer, Lauren D'Angelo. You can access today's call through the investors section on the company's website, www.alphacognition.com. Throughout this call, members of management might deliver certain forward-looking statements concerning upcoming events and how the company will perform in the future. Such forward-looking statements represent Alpha Cognition's present view of current trends and information. These forward-looking statements should not be considered guarantees of future performance and carry risks and uncertainties, among them those described in the risk factors section within the company's most recent SEC filings. Actual outcomes could differ materially from what these forward-looking statements project. For those of you who might listen to the replay, this call takes place and is being recorded on August 13, 2026. Between then and now, the company could have issued further announcements about the subjects we discuss. Please consult the company's newest press releases and current SEC filings. Alpha Cognition disclaims any duty to update these forward-looking statements unless applicable securities laws require it. I'll hand the call over now to Michael. Michael?

Michael McFadden executive
#2

Thanks, Henry. Good afternoon to all of you, and welcome to the call today. For ZUNVEYL — the first novel oral Alzheimer's therapy to gain approval in over 15 years — the second quarter of 2026 marks yet another significant quarter of commercialization. Execution was strong this quarter, with unmistakable sequential growth in demand for ZUNVEYL, broader adoption among prescribers, deeper penetration into nursing homes, and ongoing momentum in generating evidence to support ZUNVEYL clinically. We keep executing with discipline and confidence, and in my view this quarter shows that the brand's commercial trajectory is aligning well with what we expected as we keep scaling it within the long-term care segment; during Q2, net product revenues came in at roughly $6 million, which works out to about 71% growth over Q1 2026 on a quarter-over-quarter basis. Even though ZUNVEYL's trajectory pleases us, the product is still in the early stages of its commercial phase, and we stay optimistic that we will keep witnessing indicators of sustained performance and adoption of the product in the long-term care setting. Looking at the quarter, monthly prescription volumes grew stronger on a consistent basis, with high single-digit sequential gains in each month. Every KPI came in positive, among them increases in the number of prescribers, nursing home prescriptions, and repeat prescriptions. On the whole, we believe our 2026 strategic priorities remain on track as we keep driving prescription growth and constructing a durable route toward operating profitability in 2027. Now to our clinical and medical programs: during Q2 we kept advancing our evidence generation priorities, which in our view will bolster ZUNVEYL's positioning with payers as well as healthcare providers over the long term. During Q2, our top-line data from BEACON came back positive. We also launched CONVERGE, which is a retrospective review of data in long-term care, and we got RESOLVE going — picking sites, activating them, and now beginning to enroll the first patients. One thing worth highlighting: in BEACON, once providers started patients on ZUNVEYL, they saw improvements in cognition, in neuropsychiatric symptoms, and in ADLs, along with reduced polypharmacy. For those in long-term care who treat mild to moderate Alzheimer's disease, every one of those outcomes is meaningful. With these encouraging results in hand, our medical team has put the data forward for presentation at several medical meetings coming up; we're eager to share more specifics as soon as those presentations are accepted and confirmed. We're looking for CONVERGE top-line data during Q3. From where we sit, that will leave the company with two nursing home data sets, which can be shared with stakeholders to show the shifts in cognition, neuropsychiatric behaviors, and ADLs they might anticipate when ZUNVEYL is used in that setting. Henry is going to take everyone through the financials in detail in a moment, and following him, Lauren will provide a fuller commercial update. First, though, I'd like to make a few high-level comments regarding our financial position. Operating spend came to $13.5 million for the quarter, which again shows a purposeful investment in our commercial capabilities as well as in studies that back our positioning with healthcare providers and payers. Like I mentioned three months ago, I'd rather not dance around how we view this spending. We posted a net loss on our product for the quarter, and that stems from a scaling decision the company made on purpose. We're directing capital toward the parts of the business where the payoff is biggest — that means getting more prescribers on board, building real-world evidence that backs ZUNVEYL, and securing additional payer coverage. Those moves should carry us to operating profitability in 2027 and beyond, and we remain on track for that. With that, I'll turn it over to Henry.

Henry Du executive
#3

Thanks, Michael. Hello again, everyone, this afternoon. While I walk through the financial results for our second quarter of 2026, I'd ask you to also look at the press release issued today and the 10-Q that will be filed later this afternoon. In the second quarter of 2026, ZUNVEYL brought in roughly $6 million of net product revenue, versus about $3.5 million during the first quarter, which works out to sequential quarter-over-quarter growth of approximately 71%. Revenue on a total basis for the quarter came to $6.1 million, up against $1.7 million in the same period a year earlier, mainly on the strength of ZUNVEYL product sales. Now for margins. Our GAAP gross product margin for Q2 was roughly 94%, based on $6 million in net product sales against approximately $0.4 million in cost of product sales. Looking at spending, total operating expenses hit $13.5 million in the second quarter, made up of $11.5 million in SG&A and $2 million in R&D. That SG&A number shows the investments we keep making in our commercial infrastructure, payer engagement, marketing resources, and the operations of a public company. R&D reflects our continued spending on evidence generation and development programs we need to build ZUNVEYL for the long term. For Q2, we posted a net loss of $8.8 million, equal to $0.40 per share. That compares with a net loss of $13.2 million, or $0.82 per share, during the same quarter last year. At June 30, 2026, cash and cash equivalents came to $41.4 million, and total current assets were $57.9 million. With total current liabilities of $6.4 million, working capital came in at roughly $51.5 million. Also in the quarter, we completed paying off the Galantos Pharma royalty obligation ahead of schedule. That deal makes our capital structure less complicated, removes any upcoming royalties taking a cut of the product's economics, and gives us a bigger long-term share of the value ZUNVEYL generates. In our view, that was a sensible way to deploy capital and a strategic move that lifts future cash flows and makes the franchise's economics stronger as the brand keeps expanding. Our thinking remains that the capital we have now, plus the ZUNVEYL sales we expect down the road and any milestones and royalties that may come, is enough to carry us toward operating profitability in 2027. To wrap up, because ZUNVEYL has performed so well commercially and because we keep focusing on running the business efficiently, we're lowering the operating expense guidance for the full year 2026. It had been $54 million to $58 million, and now it's $50 million to $54 million. We remain dedicated to supporting ZUNVEYL's expansion and to advancing important work on evidence generation, but we've identified ways to operate more efficiently across the company. This revised guidance reflects how confident we are that we can balance investing in growth with careful expense management. So with that, I'll turn things over to Lauren, who will talk about our commercial progress. Lauren?

Lauren D'Angelo executive
#4

Thanks, Henry. I'm glad to walk everyone through a thorough look at how our commercial effort performed in Q2 2026. Last quarter we talked about momentum, and in Q2 we carried that forward with real progress on three fronts: prescriber adoption, penetration into nursing homes, and engagement with payers. What the numbers show is a story that's compelling — traction that's both durable and speeding up. Let me begin with the top line. Demand during Q2 produced net product sales of about $6 million, which works out to 71% growth over Q1 on a sequential basis; behind that figure were roughly 8,294 bottles, an increase of about 37% from quarter to quarter. Now to adoption. During Q2, our commercial team got in front of 8,194 customers in total and made calls on 3,905 prescribers — a reflection of the reach of our field organization, now right-sized at about 60 productive people, along with our ongoing work to sharpen targeting. HCP writers — those prescribers who wrote at least one prescription for ZUNVEYL — rose 27% versus the prior quarter, hitting 1,347, while cumulative writers life-to-date came to 1,908. That leaves us solidly positioned to hit or exceed the 2026 target of roughly 2,000 cumulative writers. As I've noted before, depth counts just as much as breadth. Among the 1,024 writers we had in Q2, about 76% wrote repeat prescriptions, and output per writer kept rising, reaching roughly six prescriptions each. That's evidence adoption is getting deeper, not merely broader. This kind of sustained repeat behavior ranks among the strongest indications that ZUNVEYL is making the shift from an initial trial to routine use in clinical practice. At the facility level we're seeing the same thing. The number of homes with ZUNVEYL prescriptions climbed 20% over Q1 to 1,095, with 346 new homes brought on during the quarter. Among homes that had prescriptions, about 81% reordered, which lines up with the durable facility-level adoption we talked about in Q1. The month-by-month path shows how momentum accumulated across the quarter, with sequential growth in each month and June standing as our strongest demand month to date; that exit velocity gives us clear momentum heading into Q3. Payer access is still our biggest near-term opportunity and, frankly, our biggest near-term point of friction. Rollout among the downstream plan clients during Q2 came in at roughly the same level as Q1. I want to be very direct about that. The wide-scale formulary activation we expected hasn't yet shown up at scale, and the expansion of access is lagging the access curve we laid out last quarter. Importantly, we see this as a matter of timing rather than a cap on demand. The clearest proof is that Q2 demand rose about 37% in bottles and 71% in net sales despite no widening of payer access at all. The growth in underlying prescriptions and an 81% facility repeat rate come from genuine clinical pull, not from any formulary tailwind. What that tells us is that payer conversion is still almost entirely in front of us as upside. Backing up that access work is our real-world evidence program — BEACON, CONVERGE, and RESOLVE; we anticipate these studies will provide meaningful promotional value, bolstering peer-to-peer education, strengthening conversations with payers, and building physician confidence regarding tolerability, polypharmacy management, and caregiver burden. That evidence base is already powering our education efforts. Starting in March, over 240 peer-to-peer initiatives have taken place, drawing 1,058 participants along with 325 prescribers. We likewise kept up a robust scientific showing at major congresses such as NADONA and NPA, which strengthened ZUNVEYL's standing with high-value prescribers. Taking stock, Q2 2026 showed solid commercial performance, with demand rising, conversion getting better, repeat use staying high, more prescribers coming on board, and deeper reach into facilities. Payer access hasn't widened yet, but the level of demand highlights the clinical pull behind ZUNVEYL and what lies ahead. With access gaining ground, we feel our position supports further acceleration. I'll turn things over to Michael now for closing remarks.

Michael McFadden executive
#5

Thanks, Lauren. I'd like to take a moment to walk through what I see as the main points coming out of this quarter. To start, ZUNVEYL continues to expand — we posted roughly 71% growth quarter over quarter from Q1 into Q2, and prescriptions on a monthly basis climbed steadily from April through June. Momentum on the commercial side keeps building. Next, uptake is getting deeper — we counted more than 1,300 HCP writers, more than 1,000 who wrote again, 1,000 nursing homes that filled prescriptions, and close to 900 homes that refilled. Repeat use stays among the strongest signals that a product is being adopted well. Third, we're carrying out both our commercial plan and our broader company strategy with discipline. Our commercial team is fully assembled. We're centered on putting capital to work where the business offers high returns, and our evidence generation keeps moving forward. Enrollment is open for RESOLVE, CONVERGE has begun, and BEACON wrapped up earlier than planned. Publications stemming from that trial will be shared with the medical community this fall. So we're eager about the rest of the 2026 year. The base we've established for ZUNVEYL keeps getting stronger. Our commercial metrics are trending favorably. We stay committed to executing with discipline. With that, operator, let's open it up for questions.

Ram Selvaraju analyst
#6

Thank you very much for fielding our questions, and congratulations on such a strong quarter. At this stage of the launch, I was hoping you might address three things. First, regarding repeat prescribers and the share of them who have written prescriptions across multiple months, could you provide us with more detail on that particular aspect of prescribing behavior? Specifically, what is it that turns a repeat prescriber into someone who not only writes more than one script but also remains with the product for an extended period, and do we currently have sufficient data to show what characterizes that prescriber group? Next, considering the current state of the launch, can you share your expectations for when you'll broaden commercial and promotional efforts beyond long-term care settings to reach specialist neurologists? And regarding formulary coverage, would you provide more detail on your anticipated timing for that to shift from a headwind to a tailwind, beyond the pull-through demand you're already experiencing? Thanks.

Lauren D'Angelo executive
#7

Thank you, Ram. Those are three solid questions. I'll take the first one, concerning our repeat prescriber rate and what we're seeing about what drives that repeat group to keep prescribing ZUNVEYL. I believe it really boils down to how they've experienced the drug. For many quarters now, we've been saying that breadth is where you start. You visit a large number of physicians. After you get them to give the drug a try, it takes two to three months before they truly build up that experience of monitoring the one or two patients. Then, as you'd expect, once they've observed positive results from ZUNVEYL, they'll start prescribing it again. What we're finding is that the repeat rates are substantial. 76% of providers are writing again. In my experience, that ranks among the highest I've seen. Drawing on all the feedback our customers have given us, we think there are really three factors at play. To start, their top priority is confirming that patients can handle this medication well, since their prior encounters with generic versions over the past several decades left much to be desired on the tolerability front. After they observe how well-tolerated ZUNVEYL proves to be, their attention shifts—naturally—to how effectively it works, and they notice meaningful improvements in cognition, which is the essential reason these treatments get prescribed at all. Beyond that, as we've discussed previously, they are witnessing considerable gains in behavior as well. So that amounts to three key elements; these three considerations are what drive these doctors to prescribe once more, and that response holds true everywhere. On the question of when we might move beyond long-term care into retail or the neurology area — at this point, our priority is making the most of what long-term care offers. We obviously believe there's substantial upside and plenty of runway there. The trigger point would be getting to operating profitability next year; at that stage, we'd start evaluating whether the timing is right for neurology. How payers view things is another key factor for any neurology push, and that connects directly to what you're about to ask. Going into retail without solid formulary access isn't a move anyone would want to make, because when copays run too high, abandonment rates in that channel climb significantly. So operating profitability and payer coverage are truly what would decide when we move into neurology. And then, lastly, your question about payers. Once again, we're actively talking with every major payer that truly matters for the long-term care business, and those discussions are ongoing. Our focus is on building demand so that the odds improve that we can secure formulary coverage. What we're observing everywhere, not only with ZUNVEYL specifically, but genuinely throughout the industry and in the Medicare Part D segment, is the effect of the Inflation Reduction Act, which is heavily influencing plans and the extra cost they must absorb. That's exactly why we must keep pushing demand. As we've consistently said, we're hopeful we'll see something in the second half of the year. Still, it isn't a question of if, it's a question of when, since payers absolutely acknowledge the demand and the growth we're generating, and we'll keep holding those conversations to ensure that, clearly, we begin to get formulary coverage.

Ram Selvaraju analyst
#8

Just a quick one — could you share your thinking on when CONVERGE data will be out, how much of a potential game changer that is for bending the curve upward, and also when you expect RESOLVE study data to be available? You've given guidance on when the study finishes, but I'm asking about when the data comes. Also, could you speak to how big the market opportunity is that you see as addressable with the sublingual formulation, and would you think about setting a revenue guidance range for 2027, plus perhaps an expense guidance range for that same year?

Michael McFadden executive
#9

That's quite a bit to cover. Let me begin with CONVERGE. Top-line data from CONVERGE should arrive in Q3 of 2026. What makes CONVERGE important is that it's a quantitative retrospective analysis across the whole Alzheimer's market, and it's going to give us information on persistence, adherence, polypharmacy across all drugs, and also various other things such as ADL improvement, tolerability, the kinds of patients being profiled for every drug, and so on. That data is going to lead to multiple publications; those probably won't be public until 2027. Once the study is done, we'll start writing up the data and then submit it for publication after that. We also think that combining CONVERGE quantitative data with BEACON qualitative data opens up a chance to look at that data pharmaco-economically, which will yield extra information we believe will be helpful for payers and decision-makers who have a financial stake in the way Alzheimer's drugs get used. The RESOLVE study is ongoing. It's enrolling in line with what we expected. That study should finish in Q2 of next year; data will come in the summer or fall, depending on exactly when during Q2 the RESOLVE data is provided. On the sublingual side, we're genuinely excited about that opportunity. In our view, it represents roughly 10%-20% of patients with Alzheimer's disease. The data shows that around 10%-20% of Alzheimer's patients have either aphagia or dysphagia — that means they can't swallow or they have trouble swallowing — and right now treatment options for those patients are quite limited; so we think sublingual can capture meaningful share from existing therapies and from a patch frequently applied to the torso or arm of these patients, which is pretty difficult and challenging to administer and for patients to use with that drug; we have a gating item for the sublingual product. This quarter we're running a comparative PK study; we expect that data in Q3, and that will set the timeline for the sublingual clinical program. As for revenue guidance, at this point we haven't said when we'll give revenue guidance; we will give expense guidance for 2027, and we'll probably do that right at the start of 2027 or in the latter part of Q4.

Ram Selvaraju analyst
#10

Thanks so much.

Nav Rahman analyst
#11

Hello, everybody. Congratulations on the quarter and the progress, and I appreciate you taking my questions. I only have a couple of quick ones. During the quarter, did you experience or observe any unusually large stocking or material stocking that might have affected sales? And also, if the current reimbursement and coverage is moving more slowly than expected, what do you anticipate your gross nets will be by the end of the year or throughout the year? Thanks.

Lauren D'Angelo executive
#12

Yeah, those are both really good questions. When it comes to material stocking, no, we didn't see a significant increase in stocking. Our pharmacy and our wholesalers have reached a point where they're pretty much buying on demand. What you're seeing this quarter is pure demand growth, and we feel very strongly about that because we can follow the trends and the data. When it comes to our reimbursement, obviously, right now, we're holding strong at about 74%. Obviously, if we don't see any significant formulary adds by the end of the year, we would stay pretty consistent. We'll pick up some of the IRA penalty, but it will stay within a pretty similar GTN by the end of the year.

Nav Rahman analyst
#13

Thanks. Thanks for taking my questions.

Lauren D'Angelo executive
#14

Sure.

Analyst analyst
#15

Good afternoon, everybody, and thanks for taking the questions. Jake here, filling in for Chase. July gave us yet another solid month for scripts. Could you perhaps talk a little about what demand has looked like for you so far in Q3?

Lauren D'Angelo executive
#16

Sure.

Analyst analyst
#17

How much of this is driven by plan pull-through and payer dynamics, as opposed to simply commercial execution on your team's part?

Lauren D'Angelo executive
#18

Sure. Demand and Q2 results rose each month, and June gave us our strongest demand within Q2. What I can tell you — I know we don't give guidance — is that the momentum has carried forward. In my opinion, it's all this: we've had zero formulary wins, and our 16% contracted open book of business has stayed consistent since last quarter. So in our view, that strong Q2 demand comes purely from commercial execution. We've become much smarter about targeting the right customers; we now sit at the ideal 60-person customer-facing sales force. So we think that's genuinely what's fueling the demand. That's why we like to say any formulary wins that arrive down the road are all upside for us, since we've got strong growth and we'll keep having strong growth in Q3.

Analyst analyst
#19

Thanks for that color, Lauren.

Lauren D'Angelo executive
#20

Sure.

Analyst analyst
#21

And finally, now that we're over 12 months past launch, can you discuss what adherence looks like? In what ways has it shifted as time has passed, and what figure would you put on patient retention at the six-month or 12-month mark? Present it in whatever way you prefer.

Lauren D'Angelo executive
#22

Absolutely. Adherence rates remain something we monitor, since long-term care works somewhat differently in terms of how the data gets examined. Providing an average duration of time on the drugs is difficult for me. What portion is refill business as opposed to new business. That said, what's evident to us is that within a long-term care facility, patients do remain on the drug for a longer period than in a retail segment, clearly, given that they receive daily care. Offering a specific number is something I'd rather avoid, as that adherence rate is still being worked out by us; however, here's what I can share: Q2 resulted from substantial new growth along with the refills coming from earlier quarters. I hope that down the road, I'll be in a position to provide a more precise figure regarding adherence.

Analyst analyst
#23

Yes, that would be quite useful. I appreciate your taking these questions.

Lauren D'Angelo executive
#24

Of course.

Ryan Deschner analyst
#25

Hey there, is my audio coming through?

Michael McFadden executive
#26

Yes, Ryan, we've got you loud and clear.

Ryan Deschner analyst
#27

Hi there. Sorry about that. I've got a couple of quick things to ask. First off, could you share anything about particular regions, or kinds of prescribers, or honestly any other characteristics where you're noticing the biggest expansion during this quarter and as we head into the next one? And then, when you gather input from prescribers who move their patients to ZUNVEYL, what have the main reasons behind those switches been lately, and how treatment-resistant are the patients you're starting on the drug, in terms of how many prior therapies they've tried? What does that picture look like at this point? Thanks.

Lauren D'Angelo executive
#28

Sure. When it comes to how things have grown nationwide in Q2, growth has shown up in each region. Obviously, the biggest volume is driven by those key markets where the biggest opportunity exists. On the whole, I'm happy to report that throughout the country we're witnessing fairly substantial growth, and no single area is performing dramatically better than, shall we say, another part of the country. I believe we're at last reaching a stage, with our sales team of 60 people, where momentum is building. Each region is picking up traction, so that's genuinely thrilling. On your second point, about what the feedback has been and what's driving that motivation to change. There are a number of reasons. I'd say — and we speak with customers daily — the feedback keeps astonishing us with how positively ZUNVEYL is affecting patients. We're seeing many new patients who hadn't been on any drug for some time, since they'd already not responded to donepezil. They'd already not responded to perhaps 1 or 2 generics, and nothing else was available to them. The physician feels re-energized to attempt something different for these patients, given that they couldn't tolerate certain of those drugs before. We're also seeing a considerable amount of switching, and I believe part of that stems from tolerability. It comes from — which clearly is insomnia with certain other drugs; it might be the GI problems with certain other drugs. Plus the behavioral effect. I think doctors have begun gaining experience with ZUNVEYL. They're witnessing a positive effect on behaviors. For patients who are on a different drug, they've observed behavioral improvement in patients already taking ZUNVEYL, so that's leading them to move those patients to ZUNVEYL purely based on their own experience with other patients. I'm not sure whether that addresses your question, but those 2 areas are likely the largest drivers for switching or for trying ZUNVEYL.

Ryan Deschner analyst
#29

That's really useful. Many thanks.

Dave Storms analyst
#30

Good afternoon. I appreciate you taking my questions. I'd like to begin with those prescribers who so far have only written a single prescription. Do you think there's a need to perhaps revisit and retrace your approach with them, or is there still such a large amount of runway ahead that your attention is more on the untapped opportunity?

Lauren D'Angelo executive
#31

Excellent question. A difficulty that comes with long-term care data is what we refer to as ghostwriters. It may appear in the data that they've written just one prescription, when in reality they've written additional ones. That order was simply put in under a different doctor; we don't have many physicians who tried one and then dropped off and stopped using the drug. What I can share, though, that I believe connects to your question, is that we've segmented the market, and we've clearly placed our physicians and our writers into our first tier, our second tier, where they've written several scripts, but perhaps they aren't writing it for 30% of patients. Then there's a third tier. The encouraging part of what Q2 is showing us is that each and every tier is getting better. If you recall from earlier quarters, we discussed at length those early physicians who have only tried one or two. They need two to three months to gain experience with the drug. We're now watching that wave of physicians shift into meaningful repeat writing; it's sort of an ongoing cycle where we'll keep calling on a tier 3. They're getting that two to three-month experience with the drug; they will advance into the next tier. Across every single tier, we've observed meaningful improvement; it's simply a matter of time and experience with ZUNVEYL, and we anticipate that this trend will carry on.

Dave Storms analyst
#32

That's genuinely useful detail, and I appreciate it. So perhaps only one further question about modeling. Given that the SG&A expense guidance is coming down, could you share anything additional on that front? Maybe just how persistent it might prove, and how much of it might carry over into 2027? Any extra detail there would certainly help.

Michael McFadden executive
#33

Yes, I can address that. Dave, we expect a degree of steadiness as we move into 2027, though our 2027 figures aren't locked in yet; several studies are underway during this year that push expenditures higher. Those should wrap up in Q2 of next year. Our commercial efforts and opportunities could counterbalance that as we head into 2027. So please be patient with the company while we complete our 2027 budget and spending plan, and we'll share that data, but for next year it should fall within a comparable range.

Dave Storms analyst
#34

Great. All right, thanks for fielding my questions.

William Wood analyst
#35

Hey, appreciate you addressing what we wanted to ask. We have just two items. Regarding those patients who either never stay on the drug or wind up discontinuing it — with that attrition, where they aren't persistent — what's the primary reason a patient would stop treatment? Is it side effects, or is it simply that the drug isn't working? On the other side, what causes the prescriber to quit writing it? And then, when it comes to the long-term care footprint, it seems like you keep achieving really solid growth there. I'd like to know what portion of the overall base you might eventually reach. I realize it's still early days, but how much room remains for expansion on that top-line full expansion? Thanks.

Lauren D'Angelo executive
#36

Absolutely. Those are two excellent questions. What I can share is that we speak with customers every day. We receive a great deal of feedback, and we track those patients who stop taking ZUNVEYL. Let me be clear — that doesn't mean it never occurs. I can't speak for everyone. However, we haven't encountered or been told of patients, particularly in our data, who discontinued because of tolerability or because the drug didn't work. In fact, we've heard the exact opposite. This drug is effective, and it's effective to a strong degree, and I'd say the response has been extremely favorable. Naturally, the drawback with long-term care is that these patients are extremely frail, so you will observe mortality among them. You'll also see patients who exit the long-term care facility, experience a fall, and end up admitted to the hospital. There may be an interruption; we will bring those patients back once they return home, yet the period when they appear as a discontinuation in the data is actually when they're being checked, going into the hospital. Those are likely the two largest factors. And then, obviously, should a formulary change occur or the prior authorization not get finished, our reimbursement team will follow up and make sure that patient is restarted on drugs; those would be the primary causes for seeing a patient stop ZUNVEYL. As for your question on opportunity and our base, from where I sit and where the company sits, we have considerable opportunity in long-term care. If you consider only the highest volume Alzheimer patients nationwide, and you break these out by home, roughly 5,000 homes fall into your tier 1 targets, and they offer substantial opportunity for ZUNVEYL. Then, obviously, there are approximately 3,000 top tier physicians. At present, we have around 1,000 writing. Not only must we grow the depth of those providers, but we also have many more prescribers whom we need to activate on ZUNVEYL. From where we stand, enormous upside opportunity in terms of market opportunity.

William Wood analyst
#37

Understood. If I can squeeze in one more question. Regarding the people who change medications, or who begin therapy, are you finding a larger share who don't respond to other treatments, or a larger share of switchers who are out there hunting for something? So basically, drawing from someone not currently medicated versus someone already medicated? That distinction is slight.

Lauren D'Angelo executive
#38

Right; roughly a 50/50 split is what we observe. Naturally, looking at the numbers in long-term care, lots of residents have prior exposure to these agents. For decades these medications have existed. Nothing remains for them to try. As a result, they've gone without medication for a while; so they present as never-treated, yet in reality they most likely did try something before. So we receive a large number — we'll label them never-treated — yet these are individuals who weren't taking medication, though we simultaneously witness a considerable volume of switches. Those individuals who either remain on it as of today, they're dealing with tolerability problems, they're getting serious insomnia. A lot of them already struggle with behavioral problems; that particular patient type is likely where most of our switching happens because clearly, since ZUNVEYL serves as the core foundation and delivers positive impact across each of those domains, it's a fairly straightforward change for a doctor to make. Roughly half of our business, I'd estimate, originates from people who have likely tried something and failed. They aren't on any therapy at present, but then the physician adds ZUNVEYL, or they get moved over directly from a generic acetylcholinesterase inhibitor because of the problems I just outlined.

William Wood analyst
#39

Understood. That's quite useful. Thanks for fielding what we wanted to ask, and congratulations on the quarter.

Lauren D'Angelo executive
#40

Thank you.

Michael McFadden executive
#41

Appreciate everyone joining us, and also those tuning in. We're thrilled about this quarter. It felt like a solid one, marked by expansion across bottles, prescribers, and adoption, plus momentum in payer and evidence generation, along with attention on the company's high-target opportunities that we think will keep driving growth in upcoming quarters. Thanks for being on the call. Should you want to engage with the company further, our IR contact is available via the website. Many thanks.

Operator operator
#42

That brings us to the end of today's teleconference. At this point, you're welcome to hang up your lines. We appreciate you taking part.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Alpha Cognition Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Alpha Cognition Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.